Anti-Diabetes Drugs - Malaysia | Statista Market Forecast

The revenue for the Anti-Diabetes Drugs market in Malaysia is projected to reach MYR US$167.40m in 2024.
It is expected to demonstrate an annual growth rate (CAGR 2024-2029) of 7.83%, leading to a market volume of MYR US$244.10m by 2029.
In comparison to other countries, United States is expected to generate the highest revenue, with an estimated amount of US$37.84bn in 2024.
The demand for anti-diabetes drugs in Malaysia is on the rise due to the increasing prevalence of diabetes in the country.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The demand for Anti-Diabetes Drugs in Malaysia has been on the rise in recent years.

Customer preferences: The primary customer preference in Malaysia is for oral anti-diabetic drugs. This is due to the ease of administration and convenience of taking pills. However, there is also a growing demand for insulin injections, especially among patients with advanced stages of diabetes.

Trends in the market: One of the major trends in the Anti-Diabetes Drugs market in Malaysia is the increasing prevalence of diabetes. According to the International Diabetes Federation, Malaysia has one of the highest rates of diabetes in the world. This has resulted in a growing demand for anti-diabetic drugs in the country. Another trend is the shift towards newer and more advanced anti-diabetic drugs, such as DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. These drugs offer better efficacy and safety profiles compared to older drugs like sulfonylureas and metformin.

Local special circumstances: One of the unique challenges in the Malaysian market is the high cost of anti-diabetic drugs. This is due to the country's strict drug pricing policies, which limit the prices that pharmaceutical companies can charge for their products. As a result, many patients have to rely on government-subsidized healthcare services to access affordable anti-diabetic drugs.

Underlying macroeconomic factors: The Malaysian economy has been growing steadily in recent years, which has led to an increase in disposable income among the population. This has resulted in a higher demand for healthcare services, including anti-diabetic drugs. Additionally, the government has been investing heavily in healthcare infrastructure and services, which has further boosted the demand for anti-diabetic drugs in the country. However, the high cost of these drugs remains a major challenge for many patients, especially those from low-income backgrounds.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.